Investigational drug · Phase 2
BDC-4182
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Cancer Adenocarcinoma Metastatic, Gastroesophageal Adenocarcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "BDC-4182"
First trial start
2025
May 26, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "BDC-4182", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric Cancer Adenocarcinoma Metastatic
- Gastroesophageal Adenocarcinoma
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "BDC-4182" as an intervention, largest first.
Bolt Biotherapeutics, Inc.Industry
NCT06921837 · 122 participants (planned) · Start May 26, 2025 · Primary completion May 2027
Drug: BDC-4182 · For: Gastric Cancer Adenocarcinoma Metastatic; Gastroesophageal Adenocarcinoma
Sites: Darlinghurst, Australia; Westmead, Australia; Birtinya, Australia · 16 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Gastric Cancer Adenocarcinoma Metastatic
- UtidelonePhase 38 trials
Beijing Biostar Pharmaceuticals Co., Ltd. · Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma
- MDSY-1240Phase 21 trial
Medsyn Biopharma, LLC · Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.